Idogen AB Interim report

January 1 – June 30, 2021



""Tolerogenic cell therapy has the potential to improve and prolong the life of many patients with immune driven conditions and diseases. Idogen aims to play a key role in the rapid development that is taking place in the field."

Anders Karlsson, CEO

Idogen AB (publ) Corp. Reg. no. 556756-8521 www.idogen.com

Idogen AB Interim report
April 1-June 30, 2021

Second quarter (April-June 2021)

- Other operating income amounted to KSEK 1,731 (2,782)
- Operating loss was KSEK -9,514 (-7,292)
- Loss for the period totaled KSEK -9,604 (-7,976)
- Cash flow from operating activities was KSEK -6,135 (-9,003)
- Loss per share before dilution was SEK -0.53 (-0.87) Loss per share after dilution was SEK -0.53 (-0.87)

Period (January-June 2021)

- Other operating income amounted to KSEK 3,409 (4,195)
- Operating loss was KSEK -20,164 (- 13,925)
- Loss for the period totaled KSEK -20,135 (-14,197)
- Cash flow from operating activities was KSEK -16,087 (-10,788)
- Loss per share before dilution was SEK -1.10 (-2.03). Loss per share after dilution was SEK -1.10 (-2.03)

Significant events in the second quarter

- Preparations for the application to start clinical trials made good progress.
- Documentation and qualification of the production process by Idogen's partner, the Radboud University Medical Center, continued.
- The COVID-19 pandemic affected work at the Radboud University Medical Center.

Significant events during the period

- Idogen appointed highly reputable scientific advisors in transplantation.
- A Corporate Governance section was added to the Annual Report, and Idogen is now compliant with the Nasdaq listing requirements.
- An additional payment of MSEK 3 was received from the EU's Horizon 2020 program

Significant events after the end of the period

- The European Patent Office (EPO) announced that a European patent will be granted to protect the company's tolerogenic cell therapy.
- No other significant events occurred after the end of the period that affected the results or financial position.

Condensed earnings and cash flow

(Amounts in KSEK unless otherwise stated)	2021 3 months Apr–Jun	2020 3 months Apr–Jun	2021 6 months Jan-Jun	2020 6 months Jan-Jun	2020 12 months Jan-Dec
Other operating income	1,731	2,782	3,409	4,195	8,113
Operating expenses	-11,244	-10,073	-23,573	-18,121	-34,266
Operating loss	-9,514	-7,292	-20,164	-13,925	-26,153
Loss for the period after net financial items	-9,604	-7,976	-20,135	-14,197	-26,822
Average number of shares	18,243,308	9,121,654	18,243,308	6,997,206	8,443,012
Average number of warrants	9,371,654	-	9,371,654	-	500,890
Loss per share before dilution (SEK)	-0.53	-0.87	-1.10	-2.03	-3.18
Loss per share after dilution (SEK)	-0.53	-0.87	-1.10	-2.03	-3.18
Cash flow from operating activities	-6,135	-9,003	-16,087	-10,778	28,081
KEY FIGURES					
Working capital	18,738	22,137	18,738	22,137	38,507
Acid-test ratio (%)	238	249	238	249	482
Equity/assets ratio (%)	60	63	60	63	80
Loss per share before dilution	-0.53	-0.87	-1.10	-2.03	-3.18
Average number of shares	18,243,308	9,121,654	18,243,308	6,997,206	8,443,012

All key figures in the entire report have been restated to account for the effects of a reverse split, which means that the number of shares in preceding periods has been divided by 10.

Definitions of key figures 2021

Working capital

Total current assets (including cash and cash equivalents) less current liabilities.

Acid-test ratio

Total current assets (including cash and cash equivalents) relative to current liabilities.

Equity/assets ratio

Shareholders' equity in relation to total assets.

Profit/Loss per share before dilution

Profit after tax divided by average number of shares for the period.

Average number of shares

The average number of shares from the day when the issue is registered.

Average number of warrants

The average number of warrants from the day when the issue is registered. New warrants for employees in 2021 were registered on July 6.

CEO comment

Idogen's ambition is to develop cell therapies that make it possible to prevent the body's immune system from attacking biological agents, transplanted organs or the body's own cells or tissues. Since the key component of the company's tolerogenic cell therapy platform was upgraded in mid-2019, developments have rapidly advanced. We are now ready to file an application for the first clinical trial of our most advanced project, IDO 8. The aim is to be able to offer an entirely new type of treatment for patients suffering from severe hemophilia who develop neutralizing antibodies to their life-saving treatment with coagulation factor VIII (FVIII), something that affects one in three patients. Positive trial results would provide greater hope that this patient cohort could continue with its tested standard treatment, and reduce the need to find suitable replacement therapies. This first clinical trial will also consitute the clinical proof-of-concept for our platform technology with tolerogenic cell therapy for treatment of severe and unwanted immune reactions.

Solid preparation before the start of our first clinical trial
Numerous milestones have been achieved in the development of IDO 8 in the past few years. We have contracted a world-leading manufacturer in the field of cell therapy, strengthened our patent protection, engaged in constructive dialog with regulatory authorities in several countries, appointed leading clinical experts as advisors for the project and completed a number of successful preclinical studies. All of this has formed the grounds for the application to commence a clinical trial that will be filed shortly.

Following the recruitment of a number of key individuals, we have now established a strong and competent organization that, together with our experienced advisors, is ready to take responsibility for continuing to drive the development program at a rapid pace. Our team has already proved itself – despite the COVID-19 pandemic; our outstanding flexibility and strong drive have enabled us to handle the challenges presented by the restrictions imposed on society. The clinical study is expected to be approved by the regulatory authorities at the end of the year.

Major advances in the validation of our manufacturing processes
Our partner for the manufacturing of tolerogenic cell therapy, Radboud University Medical Center in the Netherlands, has made impressive contributions to the tech transfer and qualification of each process step that was carried out in 2020 and 2021. During the pandemic, Dutch society has been faced far more stringent restrictions than what was experienced in Sweden, and local healthcare has been heavily burdened. Despite this, Radboud University Medical Center has, in close collaboration with Idogen, prepared the application to meet regulatory requirements. During this time, Professor Jolanda de Vries and her team have displayed an extremely high level of professionalism.

Interest from potential partners
An important part of Idogen's ongoing development work is to build relationships with future partners. In the second quarter, we maintained a dialog with a number of international pharmaceutical companies that have the potential to further develop and commercialize our cell therapy projects. This is an important and constant part of our work. We are currently seeing a trend of major global pharmaceutical companies adding innovative products from external companies to their project portfolios with the aim of retaining their strong market positions.

Advances for IDO 8 leading to positive results in the development of IDO T
Our development of the IDO 8 project for clinical phase has also led to advances that support that our concept that tolerogenic dendritic cells can ultimately become a platform technology for treatment of several severe conditions and diseases. The learning from the IDO 8 project can be readily transferred to the subsequent IDO T project. IDO T has the potential to become a treatment for inducing tolerance against undesirable upregulation of the immune system in connection with organ transplantations.

This creates a very interesting opportunity to treat transplant rejection. The market need is significant – 100,000 patients worldwide are undergoing kidney transplantations every year. Transplant physicians have also shown considerable interest in new treatment strategies that could reduce the need for broad immunosuppressive treatment that is currently required. A specific and individually adapted treatment is expected to result in improved long-term survival of transplanted organs and patients. We are now accelerating our development in this indication and preparing to start preclinical studies.

Tolerogenic cell therapy has the potential to improve and prolong the life of many patients with immune driven conditions and diseases. Idogen aims to play a key role in the rapid development that is taking place in the field.

Anders Karlsson
Chief Executive Officer

Idogen in brief

Idogen is a Swedish biotechnology company based in Lund. Idogen develops tolerogenic cell therapies to counteract attacks by the patient's immune system on biological agents, transplanted organs or the body's own cells or tissue. The term "tolerogenic" infers that the immune system, after treatment with Idogen's cell therapy, is assumed to be able to become tolerant to a selected disease-inducing or immunoreactive antigen.

Idogen's vision is to revolutionise the treatment of several disorders and conditions in which the body's immune system does not function as it should, and for which there is a major unmet medical need. This happens in auto-immune diseases, organ rejection after transplantation and in patients who has developed antibodies against treatment with biological drugs, e.g. factor VIII or therapeutic antibodies. Idogen's technology is based on research from Lund University.

When the immune system has become your enemy

There are many situations where the body's immune system can hurt us instead of protecting us. One example is when it causes transplant rejection. Another is when the immune system neutralises the activity of biological drugs, for example, in the treatment of hemophilia with factor VIII. Another example is autoimmune diseases – such as rheumatoid arthritis, inflammatory bowel diseases, type 1 diabetes and multiple sclerosis (MS) – where the immune system attacks the body's own proteins or antigens.



Dendritic cells control other immune system cells' recognition of, and reaction to, what belongs in the body and what is foreign. The dendritic cells that recognize bacteria or viruses activate our immune system (red) and those that recognize the body's own cells stop the body from attacking its own tissues and create tolerance (green). The goal of Idogen's cell therapy is to teach the immune system so as to counteract undesirable activation while leaving the rest of the immune system unaffected.

Idogen's technology

Idogen's treatment is based on dendritic cells – types of white blood cells – that play a central role in the immune system because they control other immune system cells' recognition of what belongs in the body (self) and what is foreign (non-self). When we are exposed to bacteria or viruses, the dendritic cells trigger our immune response. At the same time, they ensure that the immune system does not attack our own body. The dendritic cells that prevent the immune system from attacking the body's own, healthy cells are called tolerogenic. The aim of Idogen's technology is to develop tolerogenic dendritic cells specific for defined molecules or antigens.

The technology in Idogen's therapy entails that cells from the patient's blood are treated outside the body using a unique, patented method and thereby develop into antigen-specific tolerogenic dendritic cells. These tolerogenic dendritic cells are then reintroduced to the patient. In the body, these tolerogenic dendritic cells can prevent the unwanted activation of the immune system, and at the same time, the immune system is otherwise not affected.

Idogen's technology is a platform for so-called tolerogenic cell therapy which, through small changes, can be adapted to different disease state. Idogen's vision is to launch the first tolerogenic cell therapy with long-term effect for treatment of patients with great medical needs. In January 2019, the company announced that analyses conducted using an improved scientific assessment model indicated that the company's existing method had failed to produce the effect indicated in earlier preclinical trials. A comprehensive systematic evaluation of several alternative tolerance inducers therefore commenced in order to identify a more effective method for generating tolerogenic dendritic cells. In June 2019, the company was able to announce a new tolerance inducer had been developed. The newly developed method is a combination of different substances, each of which has a limited effect, but which when combined gives a synergistically powerful effect. Thereafter, the work of documenting this unique combination of substances continued until a priority patent application was filed on December 13, 2019. The patent application covers the entire Idogen technology platform for tolerogenic cell therapy. The submission is the first step towards achieving coverage to all major markets. One year later, on December 10, 2020, a final international application (PCT) was submitted. When granted, it covers market exclusivity until the year 2040.

The company evaluated the possibility of manufacturing its cell therapy externally before clinical trials on hemophilia patients and on 13 November 2019, a collaboration agreement was signed with Radboud University Medical Center in Nijmegen in the Netherlands. The study is expected to receive regulatory approval at the end of 2021.



Idogen's therapy means that cells from the patient's own blood are developed outside the body into tolerogenic dendritic cells that can specifically counter the unwanted pre-determined immune response and induce tolerance, without affecting the normal functions of the immune system. These programmed dendritic cells are then returned as a cell therapy to the patient.

Idogen's development projects



ido 8

IDO 8 – When the body's immune system attacks factor VIII, a critical medicine

IDO 8 is Idogen's most advanced project, aimed at developing a tolerogenic cell therapy for patients with severe Hemophilia A. Hemophilia A is caused by a lack of coagulation factor VIII and the usual treatment for patients with a severe form of hemophilia is to replace the missing coagulation factor. However, approximately 30 percent of patients treated with factor VIII develops inhibitory antibodies (inhibitors), which makes the treatment ineffective. This complication can often be managed by intensifying factor VIII treatment to induce tolerance, which means frequent injections of a high dose of factor VIII. Unfortunately the antibodies remain in approximately one third of these patients, which leaves patients without a way to prevent bleeding. It's for this group of vulnerable patients which Idogen's directs their treatment.



ido T

IDO T – When the body's immune system attacks a transplanted organ

A similar method to the one currently being developed for the treatment of hemophilia can also be used in other therapeutic areas with only minor adjustments to the production process. The company is therefore developing a product candidate for kidney transplantation, IDO T, in parallel. The basic principle is to "teach" the patient's immune system to recognize and accept the transplanted organ rather than attack it. This could eventually reduce or eliminate entirely the need for current methods of often lifelong immunosuppressive treatment with drugs that unselectively suppress the immune system. The company is of the opinion that there is a great need for a long-acting, cost-effective and safe treatment that induces tolerance for the transplanted organ in order to avoid the risk of organ rejection. Initially, Idogen intends to target patients about to undergo kidney transplantation with organs from living donors.



ido AID

IDO AID – When the body's immune system attacks the body's own cells and tissues

Idogen also added a third therapeutic area focusing on severe and rare autoimmune diseases, IDO AID, to its project portfolio. Idogen is currently evaluating the potential of the company's technology in a group of autoimmune diseases where there is a major unmet medical need and a treatment could be granted orphan drug designation. Patients with autoimmune diseases are often treatedfor long periods of time with powerful and broad-spectrum immuno suppressive drugs. However, the effect on the underlying disease is rarely optimal and the treatment can lead to undesirable side effects. The medical need for improved therapies is therefore high. The goal of Idogen's tolerogenic cell therapy is to dramatically reduce the need for immunosuppressive drugs by shortening the treatment, thereby improving patient outcomes.

Future and strategy

Idogen's intention is to enter into commercial license agreements based on the clinical trial results in each project. Several large pharmaceutical companies have already shown a major interest. In recent years, a number of smaller cell therapy companies have signed commercial license agreements with global pharmaceutical companies, under attractive terms.

Financial information

Financial performance for the second quarter April 1 – June 30, 2021

Other operating income
Other operating income for the quarter amounted to KSEK 1,732 (2,782).

Operating profit/loss
Operating loss for the quarter amounted to KSEK -9,514 (-7,292), a change of KSEK -2,222 compared with the year-on-year quarter. Recognition of EU research funding and other minor support generated a lower positive contribution of KSEK 1,051, while expenses rose KSEK 1,171.

Profit/loss for the quarter
Loss for the quarter totaled KSEK -9,604 (-7,976). Loss per share was SEK -0.53 (-0.87).

Liquidity and cash flow
- Cash flow from operating activities was KSEK -6,135 (-9,003).
- Cash flow from investing activities was KSEK 0 (0).
- Cash flow from financing activities was KSEK 191 (180).
- Cash flow for the quarter was KSEK -5,944 (-8,823).
- At the end of the period, the company's cash and cash equivalents amounted to KSEK 30,621 (36,008).

Financial performance for the period January 1 – June 30, 2021

Other operating income
Other operating income for the period amounted to KSEK 3,409 (4,195).

Operating profit/loss
Operating loss for the period totaled KSEK -20,164 (-13,925), a change of KSEK -6,239 compared with the year-on-year period. Recognition of EU research funding and other minor support generated a lower contribution of KSEK -786, while expenses rose KSEK 5,453.

Profit/loss for the period
Loss for the period totaled KSEK -20,135 (-14,197). Loss per share was SEK -1.10 (-2.03).

Liquidity and cash flow
- Cash flow from operating activities was KSEK -16,087 (-10,788).
- Cash flow from investing activities was KSEK -510 (0).
- Cash flow from financing activities was KSEK 177 (20,787).
- Cash flow for the quarter was KSEK -16,420 (9,998).
- At the end of the period, the company's cash and cash equivalents amounted to KSEK 30,621 (36,008).

Horizon 2020

In May 2017, Idogen was granted research funding of MEUR 2.86 (just over MSEK 29) from Horizon 2020 (the EU Framework Program for Research and Innovation) to develop the company's tolerogenic cell therapy, developed for the treatment of patients with severe hemophilia who have developed anti-factor VIII neutralizing antibodies during treatment. MSEK 3 was paid out in April. Most of the outstanding amount (MEUR 0.43 – approximately MSEK 4) is expected to be paid out in 2022.

Investments

Idogen invested in lab equipment. Investments for the period amounted to MSEK 0.5 (0.0).

Events after the end of the period

No other significant events occurred after the end of the period that affect the interim financial statements.

Employees and organization

At 30 June, the number of employees was 11.
Idogen's organization comprises all of the competencies and experience required to run the company. Close collaboration has been established with a number of key consultants in patents, preclinical, clinical trials, cell therapy, pharmaceutical development, regulatory expertise for manufacturing, documentation, quality assurance, finance and legal matters.

2021 Annual General Meeting

The Annual General Meeting (AGM) was held on May 11, 2021. The AGM was held in virtual form with postal voting. Board members Agneta Edberg (Chair), Leif G. Salford, Sharon Longhurst and Christina Herder were re-elected. The Board was expanded by one member, and Lennart Svensson was elected as new Board member. The first Corporate Governance Report was presented to the AGM, and approved. The final requirement for compliance with the Swedish Corporate Governance Code was thereby met. The Articles of Association were adjusted, and the maximum number of shares was raised to 72,960,000. The AGM also authorized the Board to implement a private placement totaling a maximum of 4,560,827 shares. Furthermore, the AGM resolved to introduce a multi-year warrants program for management and other employees. A total of 455,000 warrants were issued to eight employees and consultants for subscription of new shares in June 2024 at a price of SEK 5.79 per share.

Risks and uncertainties

In addition to general uncertainty related to research and development activities, the coronavirus pandemic and delays in the start-up of clinical trials, there are no known trends, uncertainties, potential claims or any other demands, obligations or events that are reasonably likely to have a material effect on the company's prospects. A detailed presentation of various risks can be found in the Annual Report (pages 46-50).

Equity

Equity was impacted by the new share issue and earnings during the period. At 30 June, equity amounted to MSEK 20.6 (33.2).

The share and subscription warrants

Idogen's share, which had been listed on Spotlight since June 2015, was transferred to Nasdaq First North Growth Market on June 4, 2020.

Profit/loss after tax divided by average number of shares for the period amounted to SEK -1.10 (-2.03) for the reporting period. At the end of June 2021, Idogen had approximately 3,800 shareholders. The number of shares was 18,243,308 (4,849,153 in the preceding year, recalculated after the reverse split).

There are TO4s in addition to shares. New shares will be subscribed for at 70% of the average market price between September 6-17, 2021. The price can vary between SEK 2 and SEK 5 per new share. The total number of TO4s is 9,121,654. The warrant (TO4) gives for each warrant the right to subscribe for one new share during the period 21 September to 5 October at the price calculated above.

There are two programs for management: the 2020/2023 warrants program with 250,000 subscription warrants at a market price of SEK 8.90/share, and the 2021/2024 warrants program with 455,000 subscription warrants at a market price of SEK 5.90/share. This was registered on July 6 and is not included in various calculations.

Name	No. of shares	Percentage of votes/capital (%)
Avanza Pension AB	1,672,176	9.2
Tobias Ekman	1,454,931	8.0
Formue Nord A/S	968,500	5.3
Rotheseey Ltd	476,090	2.6
Danske Bank Luxemburg	383,236	2.1
Others	13,623,279	74.7
Total	18,293,308	100.0

Accounting policies

This interim report has been prepared in accordance with RFR 2, Accounting for Legal Entities. The report has been prepared in accordance with IAS 34, with consideration for the exemptions from and amendments to IFRS specified in RFR 2. The company has no subsidiaries and does not therefore present consolidated financial statements. IFRS-compliant financial statements are not therefore applicable. The accounting policies are presented in the Annual Report on pages 56-57. No changes have been made to these policies.

Auditor's report

This interim report has not been audited.

Assurance by the Board of Directors

The Board of Directors and Chief Executive Officer certify that this interim report presents a true and fair view of the company's operations, financial position and results and describes the significant risks and uncertainties faced by the company.

Lund, August 24, 2021

Agneta Edberg
Chairman of the Board

Christina Herder
Member of the Board

Sharon Longhurst
Member of the Board

Leif G Salford
Member of the Board

Lennart Svensson
Member of the Board

Anders Karlsson
Chief Executive Officer

Condensed statement of profit or loss and other comprehensive income

(Amounts in KSEK)	2021 3 months Jan–Mar	2020 3 months Jan–Mar	2021 6 months Jan–Jun	2020 6 months Jan–Jun	2020 12 months Jan–Dec
Net sales	-	-	-	-	-
Other operating income	1,731	2,782	3,409	4,195	8,113
Total income	**1,731**	**2,782**	**3,409**	**4,195**	**8,113**
Operating expenses					
Other external costs	-7,563	-6,823	-16,720	-11,471	-21,007
Employee benefit expenses	-3,324	-2,919	-6,148	-5,987	-11,934
Depreciation of tangible assets	-357	-331	-705	-662	-1,325
Total operating expenses	**-11,244**	**-10,073**	**-23,573**	**-18,120**	**-34,266**
Operating loss	**-9,541**	**-7,292**	**-20,164**	**-13,925**	**-26,153**
Interest income and similar profit items	-83	-429	40	1	7
Interest expense and similar loss items	-8	-256	-11	-272	-677
Loss before tax	**-9,604**	**-7,976**	**-20,135**	**-14,197**	**-26,822**
Tax	-	-	-		-
PROFIT/LOSS FOR THE PERIOD	**9,604**	**-7,976**	**-20,135**	**-14,197**	**-26,822**
OTHER COMPREHENSIVE INCOME	**-**	**-**	**-**	**-**	**-**
COMPREHENSIVE INCOME FOR THE PERIOD	**-9,604**	**-7,976**	**-20,135**	**-14,197**	**-26,822**

Condensed statement of financial position

(Amounts in KSEK)	30 Jun 2021	30 Jun 2020	31 Dec 2020
ASSETS			
Tangible assets			
Leasehold improvements	355	965	660
Equipment, tools, fixtures and fittings	1,569	1,817	1,459
Total tangible assets	**1,924**	**2,782**	**2,119**
Other receivables	1,069	728	975
Prepaid expenses and accrued income	621	254	707
Cash and bank balances	30,621	36,008	47,041
Total current assets	**32,311**	**36,989**	**48,723**
TOTAL ASSETS	**34,235**	**39,771**	**50,843**
EQUITY			
Restricted equity			
Share capital	12,770	6,385	12,770
Total restricted equity	**12,770**	**6,385**	**12,770**
Non-restricted equity			
Share premium reserve	76,744	54,544	76,567
Profit/loss brought forward	-48,716	-21,894	-21,894
Profit/loss for the year	-20,135	-14,197	-26,822
Total non-restricted equity	**7,893**	**18,533**	**27,851**
Total equity	**20,663**	**24,918**	**40,621**
Current liabilities			
Accounts payable – trade	2,229	1,519	1,588
Other liabilities	328	272	342
Accrued expenses and deferred income	11,015	13,058	8,291
Total current liabilities	**13,572**	**14,852**	**10,222**
TOTAL EQUITY AND LIABILITIES	**34,235**	**39,771**	**50,843**

Condensed statement of changes in equity

(Amounts in KSEK)	Share capital	Share premium reserve	Profit/loss brought forward	Profit/loss for the year	Total equity
Opening balance at Jan 1, 2020	**3,394**	**36,829**	**10,800**	**-32,694**	**18,329**
Appropriation of profits as per AGM	-	-	-32,694	32,694	-
New share issue	2,991	22,724	-	-	25,715
Capital raising expenses	-	-4,929	-	-	-4,929
Profit/loss for the period	-	-	-	-14,197	-14,197
Closing balance at June 30, 2020	**6,385**	**54,624**	**-21,894**	**-14,197**	**24,918**

(Amounts in KSEK)	Share capital	Share premium reserve	Profit/loss brought forward	Profit/loss for the year	Total equity
Opening balance at Jan 1, 2021	**12,770**	**76,567**	**-21,894**	**-26,822**	**40,621**
Appropriation of profit/loss as per proposal to AGM	-	-	-26,822	26,822	-
New share issue	-	191	-	-	191
Capital raising expenses	-	-14	-	-	-14
Loss for the period	-	-	-	-20,135	-20,135
Closing balance at 30 June 2021	**12,770**	**76,774**	**-48,716**	**-20,135**	**20,663**

Shareholdings disclosure	**No. of shares**
Holding/value at beginning of the year	18,243,308
Holding/value at June 30, 2021	18,243,308
No. of warrants at June 30, 2021	9,371,654
Total no. of shares after conversion of warrants	**27,614,962**
Warrants registered after the end of the period	455,000

Condensed statement of cash flows

(Amounts in KSEK)	2021 3 months Apr-Jun	2020 3 months Apr-Jun	2021 6 months Jan-Jun	2020 6 months Jan-Jun	2020 12 months Jan-Dec
Operating activities					
Operating loss before financial items	-9,514	-7,292	-20,164	-13,925	-26,153
Reversal of depreciation/amortization	357	331	705	662	1,325
Interest received	-83	-429	40	1	7
Interest paid	-8	-256	-11	-272	-677
Cash flow from operating activities	**-9,248**	**-7,645**	**-19,430**	**-13,534**	**-25,498**
Increase/Decrease in prepaid expenses and accrued income	188	430	-8	754	55
Increase/Decrease in accounts payable	-242	-653	641	-664	-595
Increase/Decrease in other current liabilities	3,166	-1,134	2,710	2,656	-2,043
Cash flow from operating activities	**-6,135**	**-9,003**	**-16,087**	**-10,788**	**-28,081**
Investing activities					
Investment in intangible assets	-	-	-	-	-
Investment in tangible assets	-	-	-	-	-
Cash flow from investing activities	-	-	-	-	-
Financing activities					
New share issue	191	180	177	20,787	49,115
Cash flow from financing activities	**191**	**180**	**177**	**20,787**	**49,115**
Cash flow for the period	-5,944	-8,823	-16,420	9,998	21,033
Cash and cash equivalents at the beginning of the period	36,565	44,829	47,041	26,008	26,008
Cash and cash equivalents at the end of the period	**30,621**	**36,008**	**30,621**	**36,008**	**47,041**

Financial calender

Interim report January–September 2021	October 23, 2021
Year-end report 2021	February 9, 2022

If you have any questions, please contact:

Anders Karlsson, Chief Executive Officer
Phone: +46 (0) 709 18 00 10
Email: anders.karlsson@idogen.com

Address:

Idogen AB
Medicon Village
Scheelevägen 2
SE-223 81 Lund



This information is also available in Swedish.
The English text is an unofficial translation of the original Swedish text.
In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

When the immune system has become your enemy

Idogen develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs or the body's own cells or tissues.

idogen

Idogen AB | Medicon Village | Scheelevägen 2 | 223 81 Lund | Sweden | Email: info@idogen.com | www.idogen.com